drugset
Drugs / zabalafin
last change Nov 2025 re-read 3 minutes ago

zabalafin

Developed for
atopic eczema
Investigated by
Alphyn Biologics

Trials 1

today NCT06855745 · Ph 2
2026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06855745 Mar → Oct 2025 overdue atopic eczema Alphyn Biologics Recruiting No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2025-07-01 Alphyn Biologics Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis Highlighted in Leading Peer-Reviewed Journal alphynbiologics.com ↗
2025-04-08 Alphyn Biologics Alphyn Announces First Patient Dosed in CLEAR-AD1 Global Phase 2b Clinical Trial Program of Zabalafin Hydrogel for Atopic Dermatitis alphynbiologics.com ↗
2025-03-10 Alphyn Biologics Alphyn Poster at American Academy of Dermatology Annual Meeting Highlights Potential of Zabalafin Hydrogel as Singular, Comprehensive Treatment for Atopic Dermatitis alphynbiologics.com ↗
2024-08-27 Alphyn Biologics Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024 alphynbiologics.com ↗
2024-08-21 Alphyn Biologics Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel alphynbiologics.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as zabalafin ClinicalTrials.gov intervention name — accepted as the source's own label NCT06855745 ↗
Route Topical “Topical Zabalafin Hydrogel” NCT06855745 ↗